These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22118048)

  • 41. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
    Rathe SK; Largaespada DA
    Leukemia; 2010 Aug; 24(8):1513-5. PubMed ID: 20508618
    [No Abstract]   [Full Text] [Related]  

  • 42. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
    Rizzieri D; Vey N; Thomas X; Huguet-Rigal F; Schlenk RF; Krauter J; Kindler T; Gjertsen BT; Blau IW; Jacobsen TF; Johansen M; Bergeland T; Gianella-Borradori A; Krug U
    Leuk Lymphoma; 2014 Sep; 55(9):2114-9. PubMed ID: 24255981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.
    Parmar S; Seeringer A; Denich D; Gärtner F; Pitterle K; Syrovets T; Ohmle B; Stingl JC
    Pharmacogenomics; 2011 Apr; 12(4):503-14. PubMed ID: 21521023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.
    Åbacka H; Hansen JS; Huang P; Venskutonytė R; Hyrenius-Wittsten A; Poli G; Tuccinardi T; Granchi C; Minutolo F; Hagström-Andersson AK; Lindkvist-Petersson K
    Haematologica; 2021 Apr; 106(4):1163-1166. PubMed ID: 32554563
    [No Abstract]   [Full Text] [Related]  

  • 46. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
    Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
    Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
    Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
    Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
    Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells.
    Takagaki K; Katsuma S; Kaminishi Y; Horio T; Nakagawa S; Tanaka T; Ohgi T; Yano J
    J Biochem; 2004 Nov; 136(5):733-40. PubMed ID: 15632314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
    Taverna C; Jacky E; Sauter C
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347
    [No Abstract]   [Full Text] [Related]  

  • 52. Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy.
    Song JH; Cho KM; Kim HJ; Kim YK; Kim NY; Kim HJ; Lee TH; Hwang SY; Kim TS
    Oncol Rep; 2015 Jul; 34(1):488-94. PubMed ID: 25955569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
    Onetto N; Momparler RL; Momparler LF; Gyger M
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):231-7. PubMed ID: 2438776
    [No Abstract]   [Full Text] [Related]  

  • 54. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.
    Macanas-Pirard P; Broekhuizen R; González A; Oyanadel C; Ernst D; García P; Montecinos VP; Court F; Ocqueteau M; Ramirez P; Nervi B
    Oncotarget; 2017 Apr; 8(14):23073-23086. PubMed ID: 28160570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
    Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
    Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells.
    Zimmerman EI; Huang M; Leisewitz AV; Wang Y; Yang J; Graves LM
    FEBS Lett; 2009 Jan; 583(2):425-9. PubMed ID: 19116148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
    Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
    Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
    Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
    Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
    [No Abstract]   [Full Text] [Related]  

  • 59. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
    Levin M; Stark M; Berman B; Assaraf YG
    Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.